nach oben

European Journal of Nuclear Medicine and Molecular Imaging

Erschienen in:

22.12.2022 | Letter to the Editor

Authors’ reply to Dr. Paolo Duarte: Combined [68Ga]Ga-PSMA-11 and low-dose [18F]FDG PET/CT using a long-axial field of view scanner for patients referred for [177Lu]-PSMA-radioligand therapy

verfasst von: Ian Alberts, Robin Schepers, Konstantinos Zeimpekis, Hasan Sari, Axel Rominger, Ali Afshar-Oromieh

Erschienen in: European Journal of Nuclear Medicine and Molecular Imaging | Ausgabe 3/2023

Einloggen, um Zugang zu erhalten

Excerpt

We thank Dr. Paolo Duarte for his interest in our paper [1], for the points which he raises, and we appreciate his perspective [2]. …

Alberts I, Schepers R, Zeimpekis K, Sari H, Rominger A, Afshar-Oromieh A. Combined [68 Ga]Ga-PSMA-11 and low-dose 2-[18F]FDG PET/CT using a long-axial field of view scanner for patients referred for [177Lu]-PSMA-radioligand therapy. Eur J Nucl Med Mol Imaging. 2022. https://doi.org/10.1007/s00259-022-05961-z.CrossRef

Duarte PS. Letter to the editor: Combined [(68) Ga]Ga-PSMA-11 and low-dose [(18)F]FDG PET/CT using a long-axial field of view scanner for patients referred for [(177)Lu]-PSMA-radioligand therapy. Eur J Nucl Med Mol Imaging. 2022. https://doi.org/10.1007/s00259-022-06009-y.CrossRef

Alberts I, Hünermund J-N, Prenosil G, Mingels C, Bohn KP, Viscione M, et al. Clinical performance of long axial field of view PET/CT: a head-to-head intra-individual comparison of the Biograph Vision Quadra with the Biograph Vision PET/CT. Eur J Nucl Med Mol Imaging. 2021. https://doi.org/10.1007/s00259-021-05282-7.CrossRef

Wu Y, Feng T, Zhao Y, Xu T, Fu F, Huang Z, et al. Whole-body parametric imaging of (18)F-FDG PET using uEXPLORER with reduced scanning time. J Nucl Med. 2022;63:622–8. https://doi.org/10.2967/jnumed.120.261651.CrossRef

Hu P, Zhang Y, Yu H, Chen S, Tan H, Qi C, et al. Total-body (18)F-FDG PET/CT scan in oncology patients: how fast could it be? Eur J Nucl Med Mol Imaging. 2021. https://doi.org/10.1007/s00259-021-05357-5.CrossRef

Buteau JP, Martin AJ, Emmett L, Iravani A, Sandhu S, Joshua AM, et al. PSMA and FDG-PET as predictive and prognostic biomarkers in patients given [(177)Lu]Lu-PSMA-617 versus cabazitaxel for metastatic castration-resistant prostate cancer (TheraP): a biomarker analysis from a randomised, open-label, phase 2 trial. Lancet Oncol. 2022. https://doi.org/10.1016/S1470-2045(22)00605-2.CrossRef

Hofman MS, Emmett L, Sandhu S, Iravani A, Joshua AM, Goh JC, et al. [¹⁷⁷Lu]Lu-PSMA-617 versus cabazitaxel in patients with metastatic castration-resistant prostate cancer (TheraP): a randomised, open-label, phase 2 trial. Lancet. 397:797–804. https://doi.org/10.1016/S0140-6736(21)00237-3.

Sartor O. Invited Perspective, Outcome of patients with PSMA-PET/CT screen failure by VISION criteria and treated with 177Lu-PSMA therapy: a multicenter retrospective analysis. J Nucl Med. 2022. https://doi.org/10.2967/jnumed.122.264128.

Fundytus A, Prasad V, Booth CM. Has the current oncology value paradigm forgotten patients’ time?: too little of a good thing. JAMA Oncol. 2021;7:1757–8. https://doi.org/10.1001/jamaoncol.2021.3600.CrossRef

10.

Rauscher I, Fendler WP, Hope TA, Quon A, Nekolla SG, Calais J, et al. Can the injected dose be reduced in (68)Ga-PSMA-11 PET/CT while maintaining high image quality for lesion detection? J Nucl Med. 2020;61:189–93. https://doi.org/10.2967/jnumed.119.227207.CrossRef

11.

McCready VR, Dizdarevic S. Nuclear medicine RIP (radiation induced phobia); improving the image. Eur J Nucl Med Mol Imaging. 2018;45:2475–7. https://doi.org/10.1007/s00259-018-4168-z.CrossRef

12.

McCready VR, Dizdarevic S, Beyer T. Lesion detection and administered activity. J Nucl Med. 2020;61:1406–10. https://doi.org/10.2967/jnumed.120.244020.CrossRef

13.

Alberts I, Sachpekidis C, Prenosil G, Viscione M, Bohn KP, Mingels C, et al. Digital PET/CT allows for shorter acquisition protocols or reduced radiopharmaceutical dose in [18F]-FDG PET/CT. Ann Nucl Med. 2021;35:485–92. https://doi.org/10.1007/s12149-021-01588-6.CrossRef

14.

Alberts I, Prenosil G, Mingels C, Bohn KP, Viscione M, Sari H, et al. Feasibility of late acquisition [68Ga]Ga-PSMA-11 PET/CT using a long axial field-of-view PET/CT scanner for the diagnosis of recurrent prostate cancer-first clinical experiences. Eur J Nucl Med Mol Imaging. 2021;48:4456–62. https://doi.org/10.1007/s00259-021-05438-5.CrossRef

15.

Gafita A, Wang H, Robertson A, Armstrong WR, Zaum R, Weber M, et al. Tumor sink effect in (68)Ga-PSMA-11 PET: myth or reality? J Nucl Med. 2022;63:226–32. https://doi.org/10.2967/jnumed.121.261906.CrossRef

16.

Cook GJR, Wong WL, Sanghera B, Mangar S, Challapalli A, Bahl A, et al. Eligibility for (177)Lu-PSMA therapy depends on the choice of companion diagnostic tracer: a comparison of (68)Ga-PSMA-11 and (99m)Tc-MIP-1404 in metastatic castrate resistant prostate cancer. J Nucl Med. 2022. https://doi.org/10.2967/jnumed.122.264296.

17.

Afshar-Oromieh A, Malcher A, Eder M, Eisenhut M, Linhart HG, Hadaschik BA, et al. PET imaging with a [68Ga]gallium-labelled PSMA ligand for the diagnosis of prostate cancer: biodistribution in humans and first evaluation of tumour lesions. Eur J Nucl Med Mol Imaging. 2013;40:486–95. https://doi.org/10.1007/s00259-012-2298-2.CrossRef

18.

Iravani A, Mitchell C, Akhurst T, Sandhu S, Hofman MS, Hicks RJ. Molecular imaging of neuroendocrine differentiation of prostate cancer: a case series. Clin Genitourin Cancer. 2021;19:e200–5. https://doi.org/10.1016/j.clgc.2021.01.008.CrossRef

19.

Sachpekidis C, Kopka K, Eder M, Hadaschik BA, Freitag MT, Pan L, et al. 68Ga-PSMA-11 dynamic PET/CT imaging in primary prostate cancer. Clin Nucl Med. 2016;41:e473–9. https://doi.org/10.1097/RLU.0000000000001349.CrossRef

20.

Afshar-Oromieh A, Sattler LP, Steiger K, Holland-Letz T, da Cunha ML, Mier W, et al. Tracer uptake in mediastinal and paraaortal thoracic lymph nodes as a potential pitfall in image interpretation of PSMA ligand PET/CT. Eur J Nucl Med Mol Imaging. 2018;45:1179–87. https://doi.org/10.1007/s00259-018-3965-8.CrossRef

21.

Afshar-Oromieh A, Hetzheim H, Kubler W, Kratochwil C, Giesel FL, Hope TA, et al. Radiation dosimetry of (68)Ga-PSMA-11 (HBED-CC) and preliminary evaluation of optimal imaging timing. Eur J Nucl Med Mol Imaging. 2016;43:1611–20. https://doi.org/10.1007/s00259-016-3419-0.CrossRef

22.

Afshar-Oromieh A, Hetzheim H, Kratochwil C, Benesova M, Eder M, Neels OC, et al. The theranostic PSMA ligand PSMA-617 in the diagnosis of prostate cancer by PET/CT: biodistribution in humans, radiation dosimetry, and first evaluation of tumor lesions. J Nucl Med. 2015;56:1697–705. https://doi.org/10.2967/jnumed.115.161299.CrossRef

23.

Qin LP, Lv J, Li MZ, Xie LJ, Li JP, Li JF, et al. Biphasic GA 68-labeled prostate specific membrane antigen-11 positron emission tomography/computed tomography scans in the differential diagnosis and risk stratification of initial primary prostate cancer. Quant Imaging Med Surg. 2021;11:3619–28. https://doi.org/10.21037/qims-20-1312.CrossRef

24.

Hoffmann MA, Buchholz HG, Wieler HJ, Rosar F, Miederer M, Fischer N, et al. Dual-time point [(68)Ga]Ga-PSMA-11 PET/CT hybrid imaging for staging and restaging of prostate cancer. Cancers (Basel). 2020;12. https://doi.org/10.3390/cancers12102788.

25.

Alberts I, Huenermund JN, Sachpekidis C, Zacho HD, Mingels C, Dijkstra L, et al. Combination of forced diuresis with additional late imaging in 68Ga-PSMA-11 PET/CT – effects on lesion visibility and radiotracer uptake. J Nucl Med. 2021:jnumed.120.257741. https://doi.org/10.2967/jnumed.120.257741.

26.

Alberts I, Sachpekidis C, Dijkstra L, Prenosil G, Gourni E, Boxler S, et al. The role of additional late PSMA-ligand PET/CT in the differentiation between lymph node metastases and ganglia. Eur J Nucl Med Mol Imaging. 2020;47:642–51. https://doi.org/10.1007/s00259-019-04552-9.CrossRef

27.

Alberts I, Sachpekidis C, Gourni E, Boxler S, Gross T, Thalmann G, et al. Dynamic patterns of [(68)Ga]Ga-PSMA-11 uptake in recurrent prostate cancer lesions. Eur J Nucl Med Mol Imaging. 2020;47:160–7. https://doi.org/10.1007/s00259-019-04545-8.CrossRef

28.

Alberts I, Prenosil G, Sachpekidis C, Weitzel T, Shi K, Rominger A, et al. Digital versus analogue PET in [(68)Ga]Ga-PSMA-11 PET/CT for recurrent prostate cancer: a matched-pair comparison. Eur J Nucl Med Mol Imaging. 2020;47:614–23. https://doi.org/10.1007/s00259-019-04630-y.CrossRef

29.

Alberts I, Mingels C, Zacho HD, Lanz S, Schoder H, Rominger A, et al. Comparing the clinical performance and cost efficacy of [(68)Ga]Ga-PSMA-11 and [(18)F]PSMA-1007 in the diagnosis of recurrent prostate cancer: a Markov chain decision analysis. Eur J Nucl Med Mol Imaging. 2021. https://doi.org/10.1007/s00259-021-05620-9.CrossRef

Titel: Authors’ reply to Dr. Paolo Duarte: Combined [68Ga]Ga-PSMA-11 and low-dose [18F]FDG PET/CT using a long-axial field of view scanner for patients referred for [177Lu]-PSMA-radioligand therapy
verfasst von: Ian Alberts
Robin Schepers
Konstantinos Zeimpekis
Hasan Sari
Axel Rominger
Ali Afshar-Oromieh
Publikationsdatum: 22.12.2022
Verlag: Springer Berlin Heidelberg
Erschienen in: European Journal of Nuclear Medicine and Molecular Imaging / Ausgabe 3/2023
Print ISSN: 1619-7070
Elektronische ISSN: 1619-7089
DOI: https://doi.org/10.1007/s00259-022-06071-6

Springer Medizin

Excerpt

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 3/2023

[18F]FAPI PET/CT in the evaluation of focal liver lesions with [18F]FDG non-avidity

Preliminary efficacy of [90Y]DOTA-biotin-avidin radiotherapy against non-muscle invasive bladder cancer

Benefit of [18F] FDG PET/CT in the diagnosis and salvage treatment of recurrent nasopharyngeal carcinoma

Cross-reactivity to glutamate carboxypeptidase III causes undesired salivary gland and kidney uptake of PSMA-targeted small-molecule radionuclide therapeutics

Ultra-fast high resolution whole-body SPECT after treatment with 153Sm-EDTMP using 3D-ring CZT: applying new technology to an old tracer

Unmasking disseminated streptococcal infection: role of FDG PET/CT in diagnosis and assessing response to antibiotic treatment